Onychomycosis, commonly known as fungal nail infection, is one of the most prevalent dermatological conditions affecting the toenails. It accounts for approximately 50% of all nail disorders and affects an estimated 10% of the global population, with incidence rising sharply with age. Caused primarily by dermatophytes — particularly Trichophyton rubrum and Trichophyton mentagrophytes — as well as non-dermatophyte moulds and yeasts, the infection penetrates the nail plate and nail bed, producing characteristic features including thickening, discolouration, brittleness, and subungual debris. While traditionally managed with oral antifungal agents or topical therapies, laser treatment has emerged over the past two decades as a compelling alternative, offering a non-systemic and increasingly well-tolerated option for patients.
The Limitations of Conventional Therapy
To appreciate why laser therapy has gained traction, one must first understand the shortcomings of existing treatments. Oral antifungal agents such as terbinafine and itraconazole remain the gold standard, achieving mycological cure rates of 70–80% in clinical trials. However, they carry significant concerns: hepatotoxicity risk, drug–drug interactions, and the need for prolonged courses of treatment — often 12 weeks or more. These limitations are particularly problematic for elderly patients, who bear the greatest burden of onychomycosis and who frequently take multiple concurrent medications. Topical antifungal agents, including amorolfine lacquer and ciclopirox, circumvent systemic side effects but suffer from poor nail plate penetration, resulting in clinical cure rates typically below 10–15%. These inadequacies created the clinical impetus for laser-based alternatives.
Mechanisms of Laser Action
Laser therapy for onychomycosis operates on the principle of selective photothermolysis and direct thermal damage to fungal organisms. The nail plate and subungual space are heated to temperatures sufficient to denature fungal cell proteins and disrupt membrane integrity, ideally without causing collateral damage to surrounding host tissue. Several laser systems have been investigated, the most commonly studied being the Nd:YAG (neodymium-doped yttrium aluminium garnet) laser operating at 1064 nm, the diode laser at 870/930 nm, the carbon dioxide (CO?) laser at 10,600 nm, and more recently, fractional and photodynamic light-based systems.
The 1064 nm Nd:YAG laser is the most widely adopted platform. Its longer wavelength allows deeper tissue penetration, reaching the nail bed where fungal colonies reside, while melanin in surrounding tissue absorbs relatively less energy at this wavelength, conferring a degree of selectivity. During a typical session, the laser is passed repeatedly across the nail surface in a grid or circular pattern, raising intraungual temperature to approximately 45–60°C — a threshold associated with fungal death — while patient discomfort is managed through appropriate fluence settings and cooling intervals.
Clinical Evidence
The clinical evidence base for laser treatment has expanded considerably, though it remains heterogeneous and methodologically variable. A number of randomised controlled trials and prospective studies have demonstrated statistically significant improvements in mycological cure — defined as negative fungal culture and microscopy — following laser treatment. Cure rates in published trials vary widely, from as low as 12% to as high as 84%, reflecting differences in laser type, treatment parameters, number of sessions, patient selection, and outcome assessment timing.
Studies using the Nd:YAG laser have reported mycological cure rates of approximately 30–60% following three to six treatment sessions spaced four to eight weeks apart. Clinical improvement in nail appearance — reduced discolouration, decreased subungual hyperkeratosis — is often observed even in the absence of full mycological cure, which holds particular value for patients whose primary concern is cosmetic. Combination approaches, pairing laser treatment with topical antifungals or nail debridement, have shown promise in improving overall outcomes, suggesting that monotherapy laser treatment may not be sufficient for severe or long-standing infections.
A notable challenge in evaluating laser therapy is the slow growth of the toenail: the great toenail takes approximately 12–18 months to grow out fully. This means that clinical cure, defined as the presence of a completely normal nail, may not be assessable until well after the treatment course concludes. Many studies with shorter follow-up periods therefore capture only interim outcomes, potentially overestimating or underestimating true efficacy.
Safety Profile and Patient Tolerability
One of the most compelling attributes of laser therapy is its favourable safety profile. Unlike oral antifungals, laser treatment carries no systemic toxicity, requires no blood monitoring, and produces no drug interactions. It is therefore particularly suitable for patients with hepatic impairment, those on polypharmacy regimens, and individuals who have failed or cannot tolerate systemic therapy. Adverse effects are generally mild and transient, including localised warmth, erythema, and occasional post-procedure tenderness. Scarring and permanent nail damage are rare when appropriate protocols are followed.
The procedure is typically performed in an outpatient or podiatric clinic setting, requiring no anaesthesia, though some patients — particularly those with thicker, more dystrophic nails — experience discomfort during treatment. Nail debridement prior to laser application is commonly performed to reduce nail thickness and improve laser penetration, enhancing treatment efficacy.
Current Position in Clinical Practice
Despite its growing use, laser therapy for onychomycosis is not yet universally recognised as a first-line treatment. Regulatory approval varies by jurisdiction; in many countries, laser devices are cleared for use in onychomycosis but without the level of clinical evidence that would rank them alongside established pharmacological agents in major treatment guidelines. The cost of laser treatment — which is rarely subsidised by public health systems — remains a barrier for many patients, particularly given that multiple sessions are required.
Podiatrists and dermatologists increasingly integrate laser therapy within a broader management framework: it may be offered as an alternative for patients who cannot tolerate oral agents, as an adjunct to topical therapy in moderate disease, or as a standalone option for mild to moderate infections. Patient counselling regarding realistic expectations is essential; complete cure is not guaranteed, recurrence rates are not negligible, and the timeline to a visibly normal nail is measured in months to years.
Laser treatment represents a meaningful advance in the management of onychomycosis of the foot. Grounded in sound biophysical principles and supported by a growing body of clinical evidence, it offers an efficacious, safe, and systemically inert option in a therapeutic landscape historically dominated by drugs with significant limitations. As laser technologies evolve, treatment protocols are refined, and longer-term outcome data accumulate, the role of laser therapy is likely to consolidate further. For now, it occupies an important and expanding niche — particularly for the elderly, the medically complex, and those who have exhausted other options — signalling a genuine shift in how clinicians approach this stubborn and frequently undertreated condition.